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Abstract
Increasing numbers of human diseases are being linked to genetic variants, but our understanding of the mechanistic links
leading from DNA sequence to disease phenotype is limited. The majority of disease-causing nucleotide variants fall within
the non-protein-coding portion of the genome, making it likely that they act by altering gene regulatory sequences. We
hypothesised that SNPs within the binding sites of the transcriptional repressor REST alter the degree of repression of target
genes. Given that changes in the effective concentration of REST contribute to several pathologies—various cancers,
Huntington’s disease, cardiac hypertrophy, vascular smooth muscle proliferation—these SNPs should alter disease-
susceptibility in carriers. We devised a strategy to identify SNPs that affect the recruitment of REST to target genes through
the alteration of its DNA recognition element, the RE1. A multi-step screen combining genetic, genomic, and experimental
filters yielded 56 polymorphic RE1 sequences with robust and statistically significant differences of affinity between alleles.
These SNPs have a considerable effect on the the functional recruitment of REST to DNA in a range of in vitro, reporter gene,
and in vivo analyses. Furthermore, we observe allele-specific biases in deeply sequenced chromatin immunoprecipitation
data, consistent with predicted differenes in RE1 affinity. Amongst the targets of polymorphic RE1 elements are important
disease genes including NPPA, PTPRT, and CDH4. Thus, considerable genetic variation exists in the DNA motifs that connect
gene regulatory networks. Recently available ChIP–seq data allow the annotation of human genetic polymorphisms with
regulatory information to generate prior hypotheses about their disease-causing mechanism.
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Introduction
Genetic factors underlie the distinct phenotypic traits and
disease susceptibilities that are observed between human individ-
uals and populations [1]. Huge resources have been allocated to
mapping genetic variants - particularly the smallest, single
nucleotide variants (SNPs) - that correlate with numerous human
traits, including obesity, blood pressure, and schizophrenia [2].
While these projects have uncovered several thousand disease risk
variants, such genome-wide association studies suffer from a major
drawback: they provide little prior information or hypothesis on
the mechanism by which an associated SNP causes the observed
phenotype. Such mechanistic insight will be crucial if genetic
information is to lead to therapeutic strategies to treat genetic
diseases. Given that the majority of functional SNPs lie outside
protein-coding regions and are likely to act by altering gene
regulatory sequences, the genome-wide annotation of regulatory
SNPs represents a promising avenue for the comprehensive
prediction of SNP mechanisms-of-action [3].
It is likely that many non-coding SNPs lie within regulatory
DNA motifs, altering their affinity for transcription factors and
thus also altering the expression levels of genes cis-targeted by
those motifs. In agreement with this, variation in gene transcript
levels has been observed between individuals, and these differences
correlated with non-coding SNP alleles [4]. However, it has until
recently been difficult to establish mechanistic consequences of
SNPs at a genome-wide level because (a) most transcriptional
regulatory motifs can not be confidently identified based on DNA
sequence alone, and (b) genome-wide experimental maps of
transcription factor binding have not been available. Nevertheless,
a number of validated cases do exist where a SNP has been shown
to alter the regulation of a nearby gene: for example, a SNP in the
VEGF promoter converts non-functional DNA into a p53 response
element in 6% of genotyped individuals [5]. Indeed, it has been
shown in a small number of cases that regulatory SNPs that create
or disrupt transcriptional regulatory motifs can result in genetic
disease [6,7]. Clearly, the ultimate aim must be to comprehen-
sively annotate regulatory SNPs in human populations. In recent
years, a number of studies have employed human genome
sequence to systematically hunt for regulatory SNPs lying in the
predicted binding sites of particular transcription factors, notably
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sequence analysis alone to discover transcription factor binding
sites is plagued by high false positive rates, especially for the
majority of factors that recognise short or degenerate DNA motifs.
Recently, the development of high-throughput sequencing has
offered a solution to this problem, by enabling the genome-wide
experimental mapping of transcription factor binding sites using
the ChIPseq method [10]. Thus it is possible, for the first time, to
make highly accurate genomic annotations of regulatory SNPs
affecting transcriptional regulation.
For practical reasons, we propose that a genome-wide search for
regulatory SNPs should select a system with the following
properties: (a) the transcriptional regulatory sequence should be
clearly recognisable by motif analysis; (b) there must be an
experimentally-derived, genome-wide map for the transcription
factor in question; and (c) that transcription factor should have
known roles in human disease. In this study, we describe such a
study on the transcriptional repressor, REST (RE1-Silencing
Transcription Factor). This essential zinc finger protein represses
numerous genes in various developmental stages [11] and adult
tissues [12]. Importantly, changes in the effective nuclear levels of
REST are pathological in cancer [13,14], as well as cardiac
hypertrophy [15], vascular smooth muscle proliferation [12],
ischaemia [16] and Huntington’s disease [17]. Consequently, this
system is a promising drug target [18]. REST is recruited to target
genes by a long, characteristic motif - the RE1 (Repressor Element
1) - which can be identified with high confidence using motif-
finding methods [19]. Finally, REST was the first factor whose
binding sites were mapped by ChIPseq (chromatin immunopre-
cipitation followed by high throughput sequencing) in the human
genome [10], and since then a number of additional datasets in
various cell types have become available. In this paper, we
hypothesise that SNP variants in RE1 motifs can affect the in vivo
recruitment of REST to target genes, resulting in differential gene
repression, and altering the severity or frequency with which
individuals are affected by the abovementioned diseases.
Overall, RE1 motifs are depleted for SNPs, indicating that these
motifs are under negative evolutionary selection and that in
general, polymorphisms that affect the affinity of RE1 motifs have
a deleterious effect on their carrier [20]. Nevertheless, 8% of RE1s
contain at least one annotated SNP. In order to identify
phenotypically important SNPs that act through the modulation
of mRNA levels of REST target genes, we designed a multi-step
screen to discover polymorphic RE1 sites (henceforth referred to
as ‘‘pRE1s’’) and measured allelic affinity differences in vitro. We
present analysis of 56 SNPs that are predicted to strongly affect the
binding affinity of REST to its target genes in vivo, making them
candidate modulators of disease susceptibility.
Results
Our aim was to curate the set of genetic polymorphisms that
affect the function of REST by altering the affinity of its cognate
genomic DNA recognition elements, RE1s (Figure 1B). The RE1
consists of left and right half sites of 9 and 6 basepairs, respectively,
separated by a spacer of two nucleotides (‘‘canonical motif’’)
(Figure 1A). It was recently shown that an additional population of
binding sites contain ‘‘noncanonical’’ RE1 motifs having more or
less spacer nucleotides [10]. Genome-wide studies have also
identified REST binding regions containing one or other RE1 half
site, or indeed no identifiable RE1 motif at all, although it remains
unclear to what extent REST recruitment to these regions depends
on specific DNA recognition or whether other factors are involved
such as recruitment by another protein complex [10,21]. We
obtained an experimentally determined set of REST binding
regions in a human cell line, determined by the high-throughput
sequencing-based ChIPseq method [10] (Figure 1C). This dataset,
containing 1946 binding sites, is purely experimental and does not
explicitly contain information about the DNA motif responsible
for REST binding at each location. Thus, we passed all ChIPseq
sites through a bioinformatic motif finding filter, retaining only
those 924 instances containing an identifiable RE1 element
(Figure 1C). Importantly, we included RE1 motifs having both
canonical and non-canonical spacer configurations, but excluded
all other sites lacking both RE1 half sites within 12 nt of each
other. This validated RE1 motif set was next cross referenced to
the set of all known single nucleotide variants from dbSNP129,
yielding a set of 86 SNPs lying within 82 RE1 motifs (3 RE1s each
had 2 SNPs at distinct locations), of which 52/30 were canonical/
noncanonical, respectively. Henceforth we refer to these RE1
motifs as ‘‘Polymorphic RE1s’’ or pRE1s, and for convenience we
number them 1–82. The complete set of pRE1s can be found in
File S1. We hypothesised that these SNPs should affect the
regulation of these genes by REST in vivo, by altering their
binding affinity (Figure 1B).
The final component of the screen was an in vitro binding assay
to define the biochemical effect of SNP polymorphism on RE1
affinity. We used the competition electrophoretic mobility shift
assay that we successfully employed previously [20] to measure
REST binding to pRE1 variants. In this assay, purified
recombinant REST protein is mixed with a high affinity,
fluorescently-labelled RE1 oligonucleotide probe. The affinity of
various putative RE1 sequences can then be measured by their
ability to compete the protein:probe interaction. A comparison of
the bound and unbound probe concentrations yields a measure –
‘‘Fraction Bound’’ - that approaches 1 for a competitor sequence
that cannot bind REST, and approaches 0 for a sequence that
strongly binds REST. We refer to the more/less frequent SNP
allele as the ‘‘Major’’/‘‘Minor’’ variants, respectively. Experiments
were carried out for multiple replicates, allowing us to discern
differential affinity with statistical significance. We optimized the
EMSA conditions by maximising the Fraction Bound difference
Author Summary
Common human diseases such as cancer, heart disease, or
epilepsy have a genetic component that predisposes
particular individuals to suffer from them. Huge sums have
been invested to map the regions of the human genome
where small DNA variations, or SNPs (‘‘single-nucleotide
polymorphisms’’), determine the probability of developing
these diseases. A major problem with this approach,
however, is that, once the culprit SNPs are discovered, we
know very little about how they cause disease—which is
critical if we are to use this information to develop drugs
and therapies. In this study, we demonstrate a new
approach, employing functional maps of the human
genome that have recently been published. We begin
with regions of the genome recognised by a gene
repressor protein—REST—that is involved in a number of
important human diseases. Using information on where
REST binds in the human genome, we predict and validate
common DNA variations that increase or decrease this
binding. By affecting how much REST is recruited to
important genes, these variations may predispose or
protect individuals from a number of diseases. Studies
like this show how we can use genomic information to
gain a deeper understanding of the genetics behind
human disease.
SNPs That Alter REST Binding
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synthetic RE1 competitor sequences. In this way, we were able
to capture allelic affinity differences between high-quality RE1
sequences and their mutants (Figure 2). First, we validated the
screening approach using a series of control RE1 sequences
(designated N1-N4), containing SNPs outside the core REST
recognition motif. None of these peripheral SNPs had a detectable
effect on REST affinity (Figure 2A, 2B, 2D).
Next, we measured REST binding to the major and minor
alleles of the 82 pRE1s discovered in the bioinformatic screen
(Figure 2E). Fifty six of these exhibited significant allelic affinity
differences for REST. In most cases the minor variant was found
to bind less strongly to REST (46/56), while for the remaining
eight cases the minor variant bound more strongly (the likely
reason for this discrepancy is covered in the Discussion). This
number was found by imposing a minimum difference in Fold
Change between alleles of 0.1. If we simply use a statistical cutoff
(Pv0.05, uncorrected for multiple testing) then we find 70 pRE1s
with significantly different affinity between alleles. These data are
summarised in Figure 2E, Tables 1 and 2. Examples of three
pRE1s are shown in Figure 3. The SNP rs12565 within the pRE1
of the NPPA 39 UTR has a minor allele that strongly reduces its
binding affinity (Figure 3A). Conversely, the SNP rs6093022 in the
pRE1 upstream of the CDH4 gene strongly increases its affinity for
REST (Figure 3B). Finally, the minor allele of the SNP rs1040480,
located in pRE1-49 within an intron of the tumour-suppressor
PTPRT [22], reduces the affinity of REST (Figure 3C).
We sought to find additional evidence that the annotated target
genes in this study are indeed regulated by REST. We compared
the 78 predicted REST target genes from this study to recently
published siREST microarray expression data [23], and found
that at least 11 genes in this study respond to REST knockdown
and thus may be considered to be bona fide targets (Table 1,
Table 2, File S1). These include NPPA and CDH4 genes
mentioned above [23,12].
Several lines of evidence suggest that our EMSA method is
accurate in predicting the outcome of a SNP variant within an
RE1 element. First, we validated selected SNPs using luciferase
Figure 1. Experimental pipeline to discover SNPs that affect gene repression by REST. (A) The structure of the RE1 motif, illustrating its
two strongly constrained half sites and weakly constrained spacer and 39 regions. The spacer region may have ‘‘canonical’’ size of two nucleotides, or
other ‘‘non-canonical’’ sizes. (B) Cartoon illustrating the hypothetical effect of a SNP in an RE1 element. In the upper panel, the Major (ie more
frequent) allele contains a high-affinity RE1 sequence that strongly recruits REST, resulting in target gene repression. The presence of the SNP reduces
REST binding affinity, and results in an increase in target gene transcription. (C) The flowchart illustrates the pipeline employed in this study to
discover pRE1 SNPs.
doi:10.1371/journal.pgen.1002624.g001
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transcription of a reporter gene (Figure 4A). Consistent with
REST functioning as a transcriptional repressor, SNPs that
increased the affinity for REST (‘‘UP’’), increased the repression
of the luciferase reporter gene, and vice versa (‘‘DOWN’’). We did
not observe robust differences in reporter activity when comparing
Figure 2. Electrophoretic mobility shift assay to measure affinity differences between RE1 alleles. To measure RE1 affinity in vitro, we
employed a competition EMSA method. We tested the ability of unlabelled competitor sequences to compete for REST binding with a fluorescently
labelled DNA probe. (A) Various control oligonucleotides were used to validate the sensitivity and selectivity of the comparative EMSA assay. The
Ideal RE1 motif is a high affinity synthetic sequence we used previously [20]. By swapping two highly conserved dinucleotides in the sequence, the
affinity of the Ideal RE1 can be completely abolished (Mutated RE1). We also designed four pairs of RE1 alleles (N1-4), where SNPs lie outside the RE1
half sites, and thus would not be expected to alter binding affinity. (B) The results of control EMSAs are shown, where replicate EMSA gels have been
quantitated and plotted. The data are displayed in units of Fraction Bound (see Materials and Methods), where a low Fraction Bound value indicates
high binding affinity, and vice versa. Example raw data are shown in panels: (C) Ideal/Mutated RE1s and (D) N1 RE1s. (E) Summary results of EMSA for
all pRE1s in this study. The y-axis plots the difference in Fraction Bound between Major and Minor alleles, where the arrow begins at the value for
Major, and ends at Minor. All RE1s are ranked by their change in Fraction Bound.
doi:10.1371/journal.pgen.1002624.g002
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difference’’).
Motif analysis of the pRE1s also supports the EMSA assay
results. Transcription factor binding to DNA is guided by the
presence of a particular sequence element, and the affinity of
binding is generally in proportion to the similarity that the element
has to an idealised motif [24]. Thus, single nucleotide changes that
make an element more similar to the ideal motif are expected to
increase the element’s affinity, and vice versa. We tested this, by
using the RE1 PWM to estimate changes in pRE1 motif quality
due to the presence of a SNP (Figure 4B). We divided the RE1s
between those where the minor allele had greater affinity (‘‘UP’’),
weaker affinity (‘‘DOWN’’), or no difference. These data show that
the effect of a SNP on binding affinity agrees well the expectation
based on motif analysis: SNPs that strongly decrease the RE1
motif quality, also strongly decrease the RE1 binding affinity, and
vice versa. We also observed diversity in the strength of the effect
of SNPs depending on their location within the RE1 motif
(Figure 4C).
Finally, the degree of in vivo binding to these RE1 sites, as
measured by ChIPseq, correlates with the degree of binding
observed in the EMSA assay (Figure S1). We used REST ChIPseq
data from the ENCODE consortium to measure the degree of in
vivo binding of REST to pRE1s, and compared this to the binding
affinity discovered by EMSA. This analysis showed that REST
recruitment in vivo is significantly correlated with the RE1 motif’s
affinity, at least in GM12878 cells.
Clearly, it is important to demonstrate that changes in RE1
affinity due to observed SNPs actually alter the recruitment of
REST in the cell nucleus. It has been shown that differential
affinity of TFBS variants can be identified using allele-specific
quantitative PCR and Sanger sequencing methods [9]. We
Figure 3. SNPs may increase or decrease affinity of RE1s. Examples of SNPs that decrease (A) and increase (B) the affinity of an RE1 sequence.
On the left are diagrams of the genomic location of polymorphic RE1s, their target genes and the REST ChIPseq read density taken from ENCODE
data. On the right is corresponding quantitative EMSA data. In (A), the well-studied RE1 that lies within the 39 UTR of the NPPA gene contains the SNP
rs12565 that strongly decreases its affinity for REST. In (B), the RE1 lying distally upstream of the CDH4 gene contains the SNP rs6093022 that strongly
increases its affinity. (C) The SNP rs1040480 within an intron of PTPRT reduces the affinity of REST. B=Bound complex of REST with probe;
U=Unbound probe; D=Degradation product. The latter band represents a fraction of purified REST protein that is partially degraded, as was
observed previously [20].
doi:10.1371/journal.pgen.1002624.g003
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throughput ChIPseq should reflect a bias in allele affinity. Using
data from the ENCODE project for GM12878 cells, we searched
for sequencing reads specifically mapping to one or other pRE1
alleles, and tested for statistically significant differences in the
frequencies of reads. We chose these cells since, unlike the majority
of cell lines, they are karyotypically normal and genetic
abornamalities will not confound the analysis of allele-specific
sequencing reads. As expected, the GM12878 cells are homozy-
gous for most of the pRE1s - as evidenced by a complete absence
of read matches representing the 25mers overlapping the minor
SNP sequence variant. In the five cases shown in Figure 5, non-
zero numbers of minor allele SNP matches were observed,
indicating that the pRE1s are heterozygous in these cells. The
allelic read frequencies in all cases agree with the changes in
affinity reported by EMSA, indicating that the in vitro affinity
measurements are a good representation of the effect that a SNP
has on genomic recruitment of REST. In one case, pRE1-80, the
EMSA showed that the SNP has no effect on affinity, and this is
reflected in no significant difference in ChIPseq reads between the
two alleles. Three lines of evidence support the accuracy of this
analysis: First, we repeated the analysis for the second independent
NRSF Chipseq performed by ENCODE in GM12878 cells, and
observed the same allelic biases (Figure S2). Second, we repeated
this analysis on another karyotypically normal cell line in the
ENCODE dataset - the human H1 embryonic cell line - and again
observed allelic ChIPseq biases that were consistent with
predictions by the EMSA assay in two out of three cases (in one
case, the allelic ChIPseq reveals increased affinity of the minor
allele of pRE1-53, which is also observed in EMSA but below the
threshold we imposed) (Figure S3). Finally, we experimentally
validated these findings in the GM12878 cells using allele-specific
Table 1. Polymorphic RE1s where the minor allele has reduced affinity.
pRE1 ID Location DFB SNP ID Frequency Gene Dist(bp) Disease Association
pRE1-79 chr4:26728358 0.55 rs16878854 CEU* STIM2 256947
pRE1-73 chr16:88422513 0.53 rs1079556 ND SPIRE2 105
pRE1-64 chr11:129340555 0.50 rs12802622 CEU JPT YRI PRDM10 217828
pRE1-37 chr1:11828357 0.47 rs12565 ND NPPA 2070 Familial atrial fibrillation
pRE1-67 chr16:88422513 0.37 rs2376876 ND SPIRE2 105
pRE1-76 chr19:45318825 0.37 rs12461190 - ZNF780A 230140
pRE1-33 chr15:81129125 0.35 rs2303988 ND CPEB1 215342 Chronic lymphocytic leukemia
pRE1-82 chr9:130021147 0.32 rs36009729 ND DNM1 15663 Nicotine dependence
pRE1-34 chr3:13901643 0.30 rs12629044 CEU* WNT7A 25024 Limb deformity
pRE1-61 chr22:32763132 0.28 rs5994827 ND LARGE 2116722 Muscular dystrophy
pRE1-57 chr8:137199432 0.27 rs62526589 CEU* KHDRBS3 660550 Medulloblastoma, childhood absence
epilepsy
pRE1-65 chr11:11345063 0.27 rs16909532 - GALNTL4 255062
pRE1-70 chr10:94137238 0.27 rs11594670 - MARCH5 96338
pRE1-5-2 chr14:90031546 0.26 rs12893572 ND CALM1 98420 Osteoarthritis
pRE1-20 chr19:11320989 0.26 rs12984429 ND TMEM205 23267
pRE1-38-2 chr2:91125788 0.26 rs2599127 ND RPIA 2353497 Ribose 5-phosphate isomerase deficiency
pRE1-31-1 chr5:1476347 0.26 rs423091 ND SLC6A3 20012 Attention deficit hyperactivity disorder,
major affective disorder, tobacco addiction
pRE1-23 chr17:23114277 0.25 rs28944187 ND NOS2 37405 Hypertension, malaria infection
pRE1-32 chr1:241249144 0.25 rs61823647 ND CEP170 236102
pRE1-43 chr19:38576373 0.24 rs58865132 ND CEBPG 19924 Acute myeloid leukemia
pRE1-35 chr16:47121638 0.24 rs6500392 CEU* N4BP1 79983
pRE1-60 chr19:4720717 0.23 rs28713481 ND PGSF3 600
pRE1-5-1 chr14:90031546 0.22 rs12893721 ND CALM1 98420 Osteoarthritis
pRE1-50 chr7:64922879 0.22 rs62469938 ND VKORC1L1 252880
pRE1-62 chr3:10153511 0.22 rs6796538 CEU* VHL 24808 Erythrocytosis, pheochromocytoma, renal
cell carcinoma
pRE1-55 chr20:61747214 0.21 rs6062472 ND STMN3 8012
pRE1-42 chr20:43577393 0.20 rs6130854 ND WFDC6 24155
pRE1-72 chr15:75894622 0.19 rs55805135 ND LINGO1 2182858 Essential tremor
pRE1-19 chr22:28204664 0.19 rs59221441 ND NEFH 21555 Amyotrophic lateral sclerosis
pRE1-49 chr20:40686144 0.19 rs1040480 CHB CEU JPT YRI PTPRT 565643 Various cancers
DFB: Change in Fraction Bound value, FBMinor2FBMajor; Frequency indicates Hapmap populations where the Minor SNP allele occurs at §5% (ND-Not determined,
-v5% in all populations)(Note: genotype data come from Hapmap, except for genotyping carried out on Hapmap CEU set in this study, denoted CEU*); Dist: Distance
from RE1 to gene transcriptional start site (negative indicate upstream). Known REST target genes are underlined - see File S1 for more information.
doi:10.1371/journal.pgen.1002624.t001
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to design primers specific to major and minor pRE1 alleles in three
cases, and could confirm strongly increased binding of REST to
the major allele of pRE1-57. We could detect no difference in
binding between the alleles of pRE1-18 and pRE1-80, which
broadly reflects the results of EMSA/ChIPseq, where no
substantial difference in affinity was found.
In the course of this study, two important datasets were released:
REST (NRSF) ChIPseq data for multiple cell lines from the
ENCODE consortium [25], and updated dbSNP polymorphism
catalogues incorporating data from the 1000Genomes project
[26]. We have used this data to compile a second-generation set of
polymorphic RE1s, which can be found in Methods S1 and File
S5. Based on lessons learned in the first attempt, we modified our
analysis pipeline in several ways: RE1 motifs were scanned at low
score threshold, to improve discovery of pRE1s with higher-
affinity minor alleles; motifs were filtered through ENCODE
ChIPseq binding regions combined from five cell lines to improve
the sensitivity of motif discovery; and we only considered common
SNPs (at least 1% frequency), to avoid the discovery of extremely
rare or artifactual SNPs such as rs12565 in NPPA. Details of this
analysis can be found in Methods S1. Altogether, this second-
generation analysis yielded 628 SNPs overlapping 601 candidate
RE1s. These will form the basis of future, more sensitive analysis of
polymorphic RE1s.
Discussion
The functional annotation of phenotypic human polymor-
phisms is presently a serious bottleneck that prevents advances in
genomics from being translated into new therapies. Thus it is
imperative that, in parallel to gathering genome-wide association
data, efforts be made to annotate regulatory SNPs genome-wide.
This has been recognised and attempted by a number of groups
[27,28,29,9]. By demonstrating that regulatory polymorphisms
can be identified and characterised, we have shown that such
annotation is feasible, and allows a clear mechanistic explanation
linking noncoding DNA polymorphism with known genomic
regulatory pathways and likely disease roles.
We have shown that the genomic motifs targeted by REST
differ beween individual humans as a result of genetic polymor-
phisms. These polymorphic binding sites have different biochem-
ical affinities for REST, resulting in altered in vivo transcription
factor recruitment and differential reporter gene repression. This
results in clear and consistent changes in in vivo binding of REST,
as evidenced by our analysis of allele-specific ChIPseq reads.
The levels or activity of REST has been shown to contribute to
various pathologies [30]. For example, in Huntington’s disease,
excessive levels of REST are found in the nucleus, repressing
target genes such as BDNF and resulting in neurodegeneration
[31]. In contrast, loss of functional REST expression through
genetic mutations has been shown to contribute to colon cancer
progression [13]. Coupled with the fact that we have identified
SNPs that can either increase or decrease pRE1 affinity, these
findings suggest that pRE1s may either increase or decrease the
likelihood and/or severity of associated diseases. Clearly the next
step is to interrogate the frequency of pRE1 SNPs in genome-wide
association studies (GWAS) for REST-associated diseases, to
validate that they do indeed contribute to disease phenotypes as
predicted. This analysis has been hindered by the present lack of
availability of raw GWAS data due to patient confidentiality
issues, meaning that raw data from published studies is not
required to be freely shared, in contrast to the norm for other types
of genomic data.
The pRE1s identified in this study are often located in the
vicinity of genes involved in diseases linked to REST mediated
mis-regulation, most notably cardiovascular disease, neurological
diseases and cancer (Tables 1 and 2, and File S1). Amongst the
most promising pRE1 candidates we identified was that in the
pRE1-37, residing in the 39UTR of the NPPA gene. This encodes
the atrial natriuretic peptide, a crucial signalling peptide whose
circulating levels are strongly correlated with blood pressure [32].
Regulation of this gene by REST is a major pathway in cardiac
hypertrophy: loss of REST expression in diseased heart allows the
re-activation of the fetal cardiac gene expression program and
resultant hypertrophy [15]. A recent large scale study identified a
nearby SNP (rs5068) in the NPPA 39UTR as the single strongest
predictor within that locus of circulating ANP levels [32]. We
initially thought that the SNP in pRE1-37 (rs12565) - that was not
directly interrogated in the Newton-Cheh study - was the true
causative variant and was in linkage disequilibrium with rs5068.
However, subsequent genotyping in the Hapmap CEU cohort
indicated that these two SNPs are not linked (File S3). In fact, we
did not detect any instances of rs12565 in the 30 CEU individuals,
suggesting that it is rare. Given that the SNP reduces the affinity of
the RE1, and that REST is known to repress ANP levels within the
cardiovasculature [15], we may surmise that the minor variant
confers a tedency towards reduced blood pressure on carriers. It
Table 2. Polymorphic RE1s where the minor allele has increased affinity.
pRE1 ID Location DFB SNP ID Frequency Gene Dist(bp) Disease Association
pRE1-36 chr20:58929675 20.53 rs6093022 CEU* CDH4 2331290 Colorectal cancer, gastric cancer
pRE1-9 chr18:39881775 20.30 rs8092075 CEU* SETBP1 2633086 Acute myeloid leukemia
pRE1-24 chr8:143374761 20.25 rs28396985 CEU* TSNARE1 107683
pRE1-59 chr9:118157319 20.16 rs11356865 ND PAPPA 201427 Cardiac disease, birthweight
pRE1-6 chr10:83728154 20.16 rs11192022 ND NRG3 103077 Schizophrenia
pRE1-22 chr22:25675371 20.12 rs5761858 CEU MIAT 272933 Myocardial infarction
pRE1-69 chr22:33141085 20.12 rs9621935 ND LARGE 2494675 Muscular dystrophy
pRE1-56 chr4:3840072 20.11 rs3979 CEU* ADRA2C 101978 Congestive heart failure
DFB: Change in Fraction Bound value, FBMinor2FBMajor; Frequency indicates Hapmap populations where the Minor SNP allele occurs at §5% (ND-Not determined,
-v5% in all populations)(Note: genotype data come from Hapmap, except for genotyping carried out on Hapmap CEU set in this study, denoted CEU*); Dist: Distance
from RE1 to gene transcriptional start site (negative indicate upstream). Known REST target genes are underlined - see File S1 for more information.
doi:10.1371/journal.pgen.1002624.t002
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assays to reveal the true frequency of this polymorphism.
Our experimental method had a number of deficiencies that
may be improved in future. First, our initial scan for RE1 motifs
was performed on the reference genome, meaning that it was
biased towards discovering Major allele RE1s. Second, allelic
affinity differences were only assayed in EMSA at a single
competitor concentration which may lead to false negatives when
the free energy of binding of the allelic pair is very different from
the idealized probe. Having detailed biophysical binding models
and measuring actual binding energies would increase the
accuracy of the screen, exemplified by the automated fluorescence
anisotropy method employed by Fersht and colleagues [33].
Third, we only assayed for the presence of polymorphisms in the
minority of REST-bound genomic loci where recruitment can
unambiguously be ascribed to a high-quality, full-length RE1
element. Hopefully, future studies will shed light on the cryptic
processes mediating recruitment to the other 52% of loci
containing single half sites, or no identifiable motif at all [21,10].
Finally, many other types of genetic polymorphism exist in
addition to SNPs, the effects of which on REST targeting we have
not examined, but is likely to be important.
One important weakness in this study that only became
apparent subsequently, can be inferred from Figure 4B. While
there is a clear trend for SNPs that decrease the RE1 motif score to
also strongly decrease their binding affinity, this relationship is not
strong for SNPs that increase binding affinity. This is likely to be
result of the way we designed our analysis: We only searched for
high quality motifs in the reference genome. Therefore we
specifically selected against RE1s that have a weak motif in the
major allele, that increases in the minor allele. Those RE1s in the
present study that have higher affinity in the minor allele, are likely
to be outliers that are in fact poorly modelled by the RE1 PWM.
The other RE1s that would behave in the expected way (increase
binding affinity, increase in PWM score), are specifically selected
against, because they have a motif score below cutoff in the
reference genome, and thus were exluded from our analysis. This
weakness of our design strategy will be addressed in future.
Recent technological progress in microarray and sequencing
technologies has enabled rapid advances in human genetics,
specifically in (a) the gathering of genome-wide association data,
and (b) the depth of annotation of human genetic variants. The
latter refers specifically to the ongoing 1000Genomes Project,
which is set to revolutionise human SNP catalogues. During
preparation of this manuscript, the numbers of SNPs in dbSNP
has increased by 61% (23653737 in dbSNP131 vs 14708752 in
dbSNP129), and we thus expect that future studies will identify
similarly more pRE1s. In particular, SNPs from the 1000Genomes
project are likely to include many rarer variants that are not
represented in current annotations, and are likely to include
strongly-acting disease variants that remain undetected at present
and are posited to underlie much of the currently unexplained
genetic basis of common diseases. This means that both the
number of phenotype-associated SNPs and the total number of
known SNPs are likely to increase rapidly in the future. As a
consequence, regulatory SNP annotations will quickly become
obsolete, and will need to be repeated as genetic catalogues grow.
To account for this, we used the latest data available from
ENCODE and dbSNP to create a second generation pRE1
dataset, now comprising 628 SNPs overlapping 601 candidate
pRE1s. It is likely that these numbers will continue to increase in
the near future. We anticipate that the combination of genetics
and genomics such as that presented in this study will yield
powerful insights into the numerous polymorphisms that, in
combination, are likely determine the unique disease susceptibility
of each individual.
Materials and Methods
Discovery of SNPs in RE1 motifs
All genomic coordinates in this study are based on human
genome version hg18. ChIPseq data for REST is based on the
1946 binding peaks discovered previously in human Jurkat cells
[10]. The locations of binding peaks were converted from human
genome version hg17 to hg18 using the UCSC LiftOver tool.
Because the binding regions were of heterogeneous size, we
extended/reduced the size of each region to 100 bp centred on the
binding peak. We used the position weight matrix (PWM) search
program Seqscan [19] to identify RE1 motifs in the 100 bp
ChIPseq regions. In order to include RE1 motifs with non-
canonical spacer lengths, motif searches were carried out using
PWMs representing all possible spacer lengths from 0 to 12 bp (the
canonical RE1 contains a spacer of 2 bp). In each case, the single
highest scoring RE1 was assumed to account for REST binding.
As a result, we found 942 ChIPseq regions that contained an RE1
with a score of §0.88 from Seqscan, corresponding to a medium
stringency motif quality that is not found in appreciable numbers
in random genomic DNA. We reasoned that SNPs in the most
strongly constrained region of the RE1 motif would be most likely
to disrupt REST binding. Thus we separated all RE1s into their
left and right half sites (corresponding to positions 1–9 and 12–17
in the canonical motif), and overlapped these locations with all
SNPs of length 1 from dbSNP129, using the Galaxy package [34].
We considered the sequence variant that occurs in the human
reference genome (and usually the more frequent variant) to be the
Major allele, and the less frequent sequence variant to be the
Minor allele.
Electrophoretic mobility shift assay for comparison of
RE1 alleles
EMSAs were carried out as described previously using a 30 bp
double stranded RE1 element probe modified with 59 Cy5 label on
both strands, adapted from the rat Scn2a2 gene [35,20]. Probe was
premixed with various unlabelled competitor DNA sequences at a
molar ratio of competitor:probe 300:1, at 40C for 1 h. A master
mix containing purified recombinant HisMBP-REST/DBD
protein was then added to the premixed DNA, such that the final
reaction mixture contained 0.5 nM probe, 150 nM competitor
Figure 4. Validation and analysis of RE1 SNPs. (A) Luciferase reporter gene assay was used to test the function of pRE1 sequences. Data were
normalised to results from an ‘‘Empty’’ pGL4TK reporter gene plasmid containing no RE1 sequence. On the x-axis, RE1s are grouped according to their
performance in the EMSA assay. We included two control RE1 pairs (N2, N3) having SNPs outside their core RE1 sequence. In each case the activity of
Major and Minor RE1 alleles were tested in parallel and compared by Student’s t test (* Pƒ0.05, ** Pƒ0.01). Firefly luciferase values were normalised
to cotransfected Renilla luciferase, and values are expressed relative to the empty pGL4TJ plasmid. (B) We estimated the change in the quality of each
RE1 motif resulting from the presence of a SNP, using a position specific scoring matrix [19] (shown on the y-axis). All RE1s in this study are grouped
according to their performance in EMSA. The mean of each set is shown by a wider bar. (C) The absolute change in affinity resulting from a SNP is
plotted, as a function of the SNP location within the RE1 motif (grey bars). The absolute fold change was found by calculating the difference between
the Fraction Bound values for Major and Minor RE1 alleles. For each location, the mean value is shown by a wider bar.
doi:10.1371/journal.pgen.1002624.g004
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PLoS Genetics | www.plosgenetics.org 9 April 2012 | Volume 8 | Issue 4 | e1002624Figure 5. Allele-specific recruitment to pRE1s in GM12878 cells. The data shown corresponds to the 5 heterozygous SNPs discovered in
GM12878 cells. In all cases blue indicates the Major allele, and red the Minor allele. EMSA data is shown in left panel (Note that Fraction Bound units
correlate inversely with binding affinity), allele-specific ChIPseq read density from the ENCODE project is shown in the central panel, and allele-
specific ChIP enrichment (where available) is shown in the right panel. Statistical significance was calculated using Student’s t test (EMSA, allele-
specific ChIP) and Binomial statistics (ChIPseq).
doi:10.1371/journal.pgen.1002624.g005
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ethanol, 10 mM TrisHCl pH 8.0, 100 mM KCl, 50 M ZnCl2,
10% ultra pure glycerol, 0.1% NP-40, and 0.1 mg/ml bovine
serum albumin). This mixture was incubated at 40C for 1 h.
Unlabelled rat Chrm4 RE1 was used as a positive control
competitor (validated high affinity RE1)(‘‘Ideal’’). A mutated
version of this sequence was used as non-specific dsDNA control
competitor (‘‘Mut’’). The bound and unbound probes were
subsequently separated at 40C on a pre-run tris-glycine 12%
polyacrylamide gel at 200 V for 30 min. The fluorescence was
detected using a Typhoon 9140 PhosphorImager (Amersham),
and bound and unbound probe bands were quantified using
ImageQuant 5.2 software (Amersham). For every competitor
DNA, three independent reaction mixes were made and run on
the same gel, and all error bars and statistical tests were carried out
using these three replicates. Statistical tests were carried out using
Student’s t test (unpaired, one-sided, not corrected for multiple
testing). All quantitation data is available in File S2 and all raw
EMSA images are available from the Authors upon request.
Luciferase transcription assay
Forty base pair oligonucleotides encompassing candidate RE1s
were cloned into the pGL4 luciferase reporter plasmid (Promega),
upstream of a thymidine kinase (TK) promoter, using BglII and
KpnI restriction sites. HEK293 cells were maintained at 370C in
5% CO2 with Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal bovine serum, 4500 mg/L glucose,
4 mM L-glutamine, 100 units/ml penicillin and 100 mg/ml
streptomycin. Cells were seeded at a density of 7.56105 cells per
well in 24-well plates the day before transfection. For each well,
100 ng luciferase reporter plasmids and 5 ng pRL Renilla
transfection control plasmid were mixed and transfected using
Lipofectamine 2000 (Invitrogen) following the manufacturers
protocol. After 48 hours, cells were harvested and the reporter
activity was analyzed using Dual Luciferase Reporter Assay
(Promega) and GloMax-Multi+ chemiluminescence microplate
reader (Promega) according to the manufacturers instructions.
Three biological replicates were carried out in two technical
replicates each. Luciferase activities were normalized to the
corresponding Renilla readings, then divided by the background
activity as measured for pGL4-TK plasmids lacking the RE1
insert.
Allelic analysis of ChIPseq reads
Raw ChIPseq reads were downloaded from the ENCODE
dataset within UCSC genome browser in FASTQ format. We
employed the recently released ENCODE dataset for REST (also
known as NRSF) in GM12878 (Epstein-Barr virus transformed
lymphoblastoid cells from one of the Hapmap cohort) (25 bp
reads) and H1 (human embryonic stem cells) (35 bp reads) because
(a) these datasets has a higher number of sequencing reads than
previous ChIPseq studies on REST [10], and (b) because these
cells have normal karyotype. One can only distinguish between
reads from polymorphic regions containing a SNP, by inspection
of the sequencing reads that directly overlap that SNP. Therefore,
we used a custom script to generate all possible reads that uniquely
and exactly overlap each pRE1 SNP, that distinguish Major and
Minor variants. We considered a pRE1 to be heterozygous in a
given cell line, if it had at least 5 reads overlapping both major and
minor variants. In these cases, we compared the numbers of each
variant read using the exact binomial test in R to generate
statistical significance. We checked for heterozygous pRE1 SNPs
that could have another nearby SNP (within one ChIPseq read
length) that could confound this analysis: we identified a single
case, rs28396985, which was omitted from further analysis.
Allelic-specific ChIP
GM12878 cells were grown in RPMI media supplemented with
15% FBS and 1 mM L-glutamine. Cells were cross-linked by
adding formaldehyde directly to the media at a final concentration
of 1%. Cross-linking was quenched after 10 minutes by adding
glycine at a final concentration of 200 mM. Nuclei were obtained
by washing cells in cell lysis buffer (10 mM Tris pH 8, 0.25%
Triton-X 100, 10 mM EDTA, 0.1 M NaCl). Nuclei were lysed in
high SDS lysis buffer (50 mM Hepes pH 7.5, 150 mM NaCl1,
2 mM EDTA, 1% Triton X-100, 0.1% Na deoxycholate, 1%
SDS) and chromatin was washed twice in low SDS lysis buffer
(50 mM Hepes pH 7.5, 150 mM NaCl1, 2 mM EDTA, 1%
Triton X-100, 0.1% Na deoxycholate, 0.1% SDS). Chromatin was
sonicated to an average size of 300 bp and immuno-precipitation
was performed using REST-specific antibody (Santa Cruz).
Immunoprecipitated DNA was eluted, reverse-crosslinked and
purified by phenol:chloroform extraction. Enrichment of RE1s
was read out using quantitative real-time PCR with allele-specific
primers. Control ChIP experiments are shown in Figure S4, and
allele-specific primer sequences in File S4. We designed two
primer pairs per SNP, one for each allele (Major and Minor). One
oligo in each pair was designed such that its 39end coincided with
the SNP. To increase specificity, a mismatch was introduced in the
penultimate position. The other primer did not coincide with the
SNP nucleotide and was shared between the pairs. To calculate
enrichment for the ChIP-enriched DNA, we normalized the Ct
values obtained for the SNP-specific product with the Ct values
obtained from amplifying a locus in a GAPDH exon (non-target
control) to generate Delta Ct values. These were further
normalized to Input (non-immunoprecipitated DNA), and fold
enrichment was calculated by the DeltaDelta Ct method.
Supporting Information
Figure S1 Correlation of in vivo recruitment to in vitro affinity
of pRE1s.Using raw ENCODE ChIPseq reads, binding peaks
were recovered using MACS [36] at default settings. Relevant
control Input libraries were used for normalisation. ChIPseq
enrichment values for each pRE1 were plotted against the relative
binding from EMSA - defined as (1 - Fraction Bound). The non-
parametric Spearman method was used to compute the correla-
tion between Enrichment and Fraction Bound. This correlation is
expected to be negative, since the value of Fraction Bound
decreases with the increasing binding. Statistical significance of
these correlations is also shown. Two available replicates of each of
GM12878 and H1 cell lines were analysed independently.
(PDF)
Figure S2 Allele-specific ChIPseq reads in two independent
biological replicates. Identical analysis was carried out on the two
GM12878 NRSF (REST) ChIPseq libraries available from the
ENCODE consortium. Charts show the number of uniquely
mapping reads originating from Major or Minor alleles of pRE1s
found to be heterozygous in GM12878. The data in the left panel
(Replicate 1) correspond to those shown in Figure 5 of the main
text.
(PDF)
Figure S3 Allelle-specific ChIPSeq analysis in H1 cell line.
Using data from the ENCODE consortium, we extracted those
sequencing reads mapping uniquely and specifically to all pRE1s.
We identified three heterozygous cases having non-zero reads for
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PLoS Genetics | www.plosgenetics.org 11 April 2012 | Volume 8 | Issue 4 | e1002624both major and minor alleles, shown here. The figures show the
density of reads at each position around the relevant SNP for
Major (blue) and Minor (red) alleles. Left panel shows EMSA data
(Note that units are in Fraction Bound, which is inversely
correlated to binding affinity), right panel shows ChIPseq read
density. Statistical significance was calculated using Student?s t test
(EMSA) and Binomial statistics (ChIPseq).
(PDF)
Figure S4 Control experiments for allel-specific ChIP. Shown
are enrichment values for conventional ChIP carried out using an
anti-REST antibody in GM12878 cells. ACTB and RPL amplicons
are not proximal to any REST binding site, and thus are not
expected to show enrichment. Data is also shown for conventional
primer sets (ie not allele-specific) to pRE1s indicated, where REST
is expected to be recruited.
(PDF)
File S1 Complete list of polymorphic RE1s identified in this
study (First Generation pRE1 Catalogue).
(XLS)
File S2 Raw EMSA quantification data.
(XLS)
File S3 Genotyping of pRE1s in CEU Hapmap population.
(XLS)
File S4 ChIP qPCR primer sequences.
(DOC)
File S5 Complete list of polymorphic RE1s identified in the
Second Generation pRE1 Catalogue.
(XLS)
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